Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
高度な化学プロジェクトに向けた有機合成、カスタム合成、プロセス開発、スケールアップ支援。
複雑分子に向けた合成・分析技術。
CHEMOSは、合成を基盤とするCDMOとして、有機合成、カスタム合成、ルート開発、プロセス開発、スケールアップ支援、分析サポートに取り組んでいます。
CHEMOSのニュース、インサイト、更新情報。
FDA announced on July 16, 2026 that Lipfendra (enlicitide) was approved to be used with diet and exercise to reduce LDL-C in adults with high cholesterol or heterozygous familial hypercholesterolemia. FDA also states that Lipfendra is a tablet taken by mouth once daily and is the first oral therapy that blocks PCSK9.
続きを読むThe key correction is that the ACS Organic Process Research & Development paper describes LUNA18 (paluratide) through a liquid-phase peptide synthesis process, not a simple SPPS plus three-fragment route. The paper’s abstract says the authors departed from conventional solid-phase peptide synthesis and developed an LPPS process for an N-alkyl-rich cyclic undecapeptide KRAS inhibitor.
続きを読む
The reported inclisiran architecture illustrates why an siRNA conjugate cannot be reduced to a sequence plus a targeting ligand. Descriptions of that architecture place a triantennary N-acetylgalactosamine (GalNAc) unit at the sense-strand terminus, combine 2'-fluoro and 2'-O-methyl ribose substitutions with terminal phosphorothioate linkages, and rely on the antisense strand for RNA-induced silencing complex (RISC) loading. Each element addresses a different constraint: cell uptake, nuclease exposure, strand handling, or intracellular recognition.
初期ルート評価からプロセス開発、スケールアップまで、CHEMOSはR&D経験と生産基盤でカスタム合成を支援します。
